Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | CLPP | Q16740 | 1/20 | 0.42 |
| ▸ | CALCA | P06881 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209177 | 0.92 | ALDH1A1 (0.52) | TP53ALDH1A1PRKAA2KCNH2CYP2C9 | |
| SCHEMBL1376535 | 0.83 | MAPT (0.61) | TP53ALDH1A1KCNH2CYP2C9MAPT | |
| SCHEMBL1750602 | 0.83 | MAPT (0.63) | TP53ALDH1A1KCNH2CYP2C9MAPT | |
| SCHEMBL1376994 | 0.82 | MAPT (0.60) | TP53ALDH1A1KCNH2CYP2C9MAPT | |
| SCHEMBL2203924 | 0.82 | KCNH2 (0.51) | TP53ALDH1A1PRKAA2KCNH2CYP2C9 | |
| SCHEMBL2204798 | 0.82 | MAPT (0.51) | TP53ALDH1A1KCNH2CYP2C9MAPT | |
| SCHEMBL4397417 | 0.82 | SCD (0.52) | TP53ALDH1A1PRKAA2KCNH2CYP2C9 | |
| SCHEMBL2207526 | 0.81 | SCD (0.52) | TP53ALDH1A1PRKAA2KCNH2CYP2C9 | |
| SCHEMBL87295 | 0.81 | KCNH2 (0.51) | TP53ALDH1A1KCNH2CYP2C9MAPT | |
| SCHEMBL2204304 | 0.80 | KCNH2 (0.53) | TP53ALDH1A1KCNH2CYP2C9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | SUMMA VINCENZO | 2011-10-20 | — | — | US | claimed |
| US-20090253681-A1 | HIV Integrase Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-10-08 | — | — | US | claimed |
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | SUMMA VINCENZO | 2011-10-20 | — | — | US | disclosed |
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | SUMMA VINCENZO | 2011-10-20 | — | — | US | disclosed |
| US-7981879-B2 | HIV integrase inhibitors | Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2011-07-19 | — | — | US | disclosed |
| US-7981879-B2 | HIV integrase inhibitors | Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2011-07-19 | — | — | US | disclosed |
| US-20090253681-A1 | HIV Integrase Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-10-08 | — | — | US | disclosed |
| US-20090253681-A1 | HIV Integrase Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257162-A1 | HIV INTEGRASE INHIBITORS | REV1, CDK9, INTS9 | TP53 1367/4885ALDH1A1 4016/4885PRKAA2 3511/4885 |
| US-20090253681-A1 | HIV Integrase Inhibitors | REV1, INTS9, H1-10 | TP53 871/4885ALDH1A1 4120/4885PRKAA2 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.